Compare Eli Lilly And Co (LLY) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs LYFT Inc — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while LYFT Inc trades at $16.21 (market cap $6.11B). The key difference: Eli Lilly And Co is far larger — about 170.2× LYFT Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while LYFT Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and LYFT Inc for 47 Days on average.
| LLY | LYFT | |
|---|---|---|
Market Cap | $1.04T | $6.11B |
Volume | 3,064,878 | 13,504,560 |
Sector | Health | Technology |
52-Week High | $1.28K | $24.57 |
52-Week Low | $799.57 | $12.65 |
Typical Hold Time | 93 Days | 47 Days |
Enterprise Value | $1.09T | $5.57B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Lyft (LYFT) trades at $16.22, up 3.97% with a bullish technical signal. The company shows strong profitability with 45.52% gross margins and 42.32% net income margin, though recent earnings missed expectations. Revenue growth continues from $4.1B in 2022 to $6.32B in 2025. Recent developments include European expansion and a $272.5M legal settlement. The stock trades below the $18.07 consensus price target with 22 buy, 35 hold, and 3 sell ratings.
Lyft presents a mixed outlook with strong cash flow generation and expanding operations balanced against recent earnings misses and competitive pressures. The bullish technical setup and below-consensus pricing suggest potential upside, but investors face risks from driver classification lawsuits, market volatility, and execution challenges in new markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
